Post hoc analysis of the phase 3 EXPAND trial in secondary progressive MS: siponimod reduced risk of sustained EDSS ≥7.0 (requiring a wheelchair) vs placebo (HR 0.60; 95% CI 0.41–0.88); HR 0.49 in active SPMS, non-significant in non-active SPMS (HR 0.78).
Secondary analysis
Vermersch et al. Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study